A. DiFrancesco

675 total citations
12 papers, 522 citations indexed

About

A. DiFrancesco is a scholar working on Rheumatology, Surgery and Molecular Biology. According to data from OpenAlex, A. DiFrancesco has authored 12 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 3 papers in Surgery and 3 papers in Molecular Biology. Recurrent topics in A. DiFrancesco's work include Osteoarthritis Treatment and Mechanisms (7 papers), Knee injuries and reconstruction techniques (3 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (2 papers). A. DiFrancesco is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (7 papers), Knee injuries and reconstruction techniques (3 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (2 papers). A. DiFrancesco collaborates with scholars based in United States, Malaysia and Mexico. A. DiFrancesco's co-authors include Allan Gibofsky, Yusuf Yazıcı, J. Tambiah, Marc C. Hochberg, Christopher J. Swearingen, Timothy E. McAlindon, Nancy E. Lane, Nebojša Skrepnik, İsmail Şimşek and Morgan H. Jones and has published in prestigious journals such as Clinical Cancer Research, Annals of the Rheumatic Diseases and Vaccine.

In The Last Decade

A. DiFrancesco

11 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. DiFrancesco United States 8 259 139 137 126 111 12 522
Daichi Hoshina Japan 13 64 0.2× 61 0.4× 74 0.5× 107 0.8× 75 0.7× 25 397
Elizabeth Hutto United States 8 91 0.4× 149 1.1× 24 0.2× 151 1.2× 105 0.9× 10 569
Fumitaka Shiozawa Japan 9 161 0.6× 148 1.1× 22 0.2× 128 1.0× 140 1.3× 12 448
Toshiyuki Ikeda Japan 13 147 0.6× 107 0.8× 22 0.2× 221 1.8× 86 0.8× 26 564
Claire Deligne France 8 88 0.3× 173 1.2× 33 0.2× 97 0.8× 142 1.3× 18 415
GS Firestein United States 10 243 0.9× 125 0.9× 23 0.2× 187 1.5× 137 1.2× 16 534
E.U. Sumer Denmark 10 244 0.9× 54 0.4× 96 0.7× 169 1.3× 57 0.5× 12 497
T Leizer Australia 11 172 0.7× 181 1.3× 27 0.2× 118 0.9× 113 1.0× 15 541
Hye-Joa Oh South Korea 8 127 0.5× 158 1.1× 19 0.1× 131 1.0× 89 0.8× 9 395
Rutvi Shah India 3 198 0.8× 260 1.9× 15 0.1× 202 1.6× 168 1.5× 9 674

Countries citing papers authored by A. DiFrancesco

Since Specialization
Citations

This map shows the geographic impact of A. DiFrancesco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. DiFrancesco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. DiFrancesco more than expected).

Fields of papers citing papers by A. DiFrancesco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. DiFrancesco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. DiFrancesco. The network helps show where A. DiFrancesco may publish in the future.

Co-authorship network of co-authors of A. DiFrancesco

This figure shows the co-authorship network connecting the top 25 collaborators of A. DiFrancesco. A scholar is included among the top collaborators of A. DiFrancesco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. DiFrancesco. A. DiFrancesco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Maher, Toby M., John Hood, Jim Pitman, et al.. (2025). Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Respiratory Medicine. 13(11). 1001–1010.
2.
3.
Yazıcı, Yusuf, T.E. McAlindon, Allan Gibofsky, et al.. (2021). A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis and Cartilage. 29(5). 654–666. 73 indexed citations
4.
5.
Yazıcı, Yusuf, Timothy E. McAlindon, Allan Gibofsky, et al.. (2019). Efficacy and safety from a phase 2B trial of SM04690, a novel, intra-articular, WNT pathway inhibitor for the treatment of osteoarthritis of the knee. Osteoarthritis and Cartilage. 27. S503–S503. 9 indexed citations
6.
Yazıcı, Yusuf, Timothy E. McAlindon, Allan Gibofsky, et al.. (2019). THU0458  EFFICACY AND SAFETY FROM A PHASE 2B TRIAL OF SM04690, A NOVEL INTRA-ARTICULAR WNT PATHWAY INHIBITOR FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE. Annals of the Rheumatic Diseases. 78. 519–519. 9 indexed citations
7.
Yazıcı, Yusuf, Timothy E. McAlindon, Allan Gibofsky, et al.. (2018). Results from a 52-week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis. Osteoarthritis and Cartilage. 26. S293–S294. 17 indexed citations
8.
Yazıcı, Yusuf, Timothy E. McAlindon, Allan Gibofsky, et al.. (2018). SAT0586 Results from a 52 week randomised, double-blind, placebo-controlled, phase 2 study of a novel, wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment. Annals of the Rheumatic Diseases. 77. 1146–1147. 3 indexed citations
9.
Yazıcı, Yusuf, Timothy E. McAlindon, Roy Fleischmann, et al.. (2017). A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis and Cartilage. 25(10). 1598–1606. 108 indexed citations
10.
11.
Gluck, William Larry, Deborah Hurst, Alan R. Yuen, et al.. (2004). Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma. Clinical Cancer Research. 10(7). 2253–2264. 127 indexed citations
12.
Boyce, Thomas G., Henry H. Hsu, Edith C. Sannella, et al.. (2000). Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine. 19(2-3). 217–226. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daichi Hoshina Breakdown of academic impact, for papers by Elizabeth Hutto Breakdown of academic impact, for papers by Fumitaka Shiozawa Breakdown of academic impact, for papers by Toshiyuki Ikeda Breakdown of academic impact, for papers by Claire Deligne Breakdown of academic impact, for papers by GS Firestein Breakdown of academic impact, for papers by E.U. Sumer Breakdown of academic impact, for papers by T Leizer Breakdown of academic impact, for papers by Hye-Joa Oh Breakdown of academic impact, for papers by Rutvi Shah
Rankless by CCL
2026